Get the Stockscreener App
68.78
0.30%
-0.21
After Hours:
69.20
0.42
+0.61%
Bridgebio Pharma Inc stock is traded at $68.78, with a volume of 2.12M.
It is down -0.30% in the last 24 hours and down -5.97% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$68.99
Open:
$69.81
24h Volume:
2.12M
Relative Volume:
0.80
Market Cap:
$13.33B
Revenue:
$502.08M
Net Income/Loss:
$-732.94M
P/E Ratio:
-18.18
EPS:
-3.7842
Net Cash Flow:
$-455.50M
1W Performance:
-1.33%
1M Performance:
-5.97%
6M Performance:
+9.77%
1Y Performance:
+79.96%
1-Day Range:
$67.48
$70.42
1-Week Range:
$67.48
$72.49
52-Week Range:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
68.78 | 13.37B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio to present encaleret data at endocrinology congress By Investing.com - Investing.com South Africa
BridgeBio Pharma to Present Phase 3 Infigratinib Achondroplasia Trial Results at ECE 2026, Focusing on Annualized Growth Velocity in Children Aged 3-11 - geneonline.com
MSN Money - MSN
BridgeBio to unveil Phase 3 rare-disease trial results in Prague - Stock Titan
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE - Yahoo Finance
BBIO SEC FilingsBridgebio Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
Achondroplasia Pipeline Expands as 15+ Pharma Companies - openPR.com
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 - The Manila Times
New heart failure data on BridgeBio drug lands late-breaking ESC slot - Stock Titan
William Blair Initiates BridgeBio Pharma(BBIO.US) With Buy Rating - Moomoo
BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This Stock - Insider Monkey
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Q2 2025 Earnings Transcript - AOL.com
(BBIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Truist Financial Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $102 - Moomoo
Truist Financial Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET - The Manila Times
After the bell: BridgeBio schedules Q1 results and program update - Stock Titan
Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore (NASDAQ:BBIO) - Seeking Alpha
BridgeBio rises after late-stage trial win for dwarfism therapy - MSN
BridgeBio Pharma Is Maintained at Buy by Truist Securities - Moomoo
BridgeBio earnings on deck: Can Attruby sustain rapid growth? By Investing.com - Investing.com South Africa
BridgeBio earnings on deck: Can Attruby sustain rapid growth? - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Wave Life Sciences (WVE) - The Globe and Mail
BBIO Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates BridgeBio Pharma stock rating on stable Vyndamax outlook - Investing.com Canada
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Moody Aldrich Partners LLC - MarketBeat
HC Wainwright Predicts Weaker Earnings for BridgeBio Pharma - MarketBeat
Pictet Asset Management Holding SA Has $96.96 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Teachers Retirement System of The State of Kentucky Buys 17,343 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman By Investing.com - Investing.com South Africa
BridgeBio launches ATTR-CM awareness campaign with Morgan Freeman - Investing.com UK
BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity - Investing.com Canada
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
Raymond James reiterates BridgeBio stock rating on Vyndamax settlement By Investing.com - Investing.com Canada
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $106 - Moomoo
BBIO Reiterated by Mizuho -- Price Target Maintained at $106 - GuruFocus
Barclays sees Pfizer IP case progress as positive for BridgeBio stock - Investing.com Canada
Pfizer deals extend patent life for a top-selling rare disease drug - BioPharma Dive
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):